The latest price target for Macrogenics (NASDAQ:MGNX) was reported by HC Wainwright & Co. on November 3, 2025. The analyst firm set a price target for $2.00 expecting MGNX to rise to within 12 months (a possible 48.15% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Macrogenics (NASDAQ:MGNX) was provided by HC Wainwright & Co., and Macrogenics reiterated their neutral rating.

The last upgrade for Macrogenics Inc happened on April 9, 2024 when TD Cowen raised their price target to N/A. TD Cowen previously had a hold for Macrogenics Inc.

The last downgrade for Macrogenics Inc happened on November 7, 2024 when JMP Securities changed their price target from N/A to N/A for Macrogenics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Macrogenics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Macrogenics was filed on November 3, 2025 so you should expect the next rating to be made available sometime around November 3, 2026.

While ratings are subjective and will change, the latest Macrogenics (MGNX) rating was a reiterated with a price target of $2.00 to $2.00. The current price Macrogenics (MGNX) is trading at is $1.35, which is out of the analyst’s predicted range.